These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20153840)

  • 1. Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation.
    Shu X; Nelbach L; Ryan RO; Forte TM
    Biochim Biophys Acta; 2010 May; 1801(5):605-8. PubMed ID: 20153840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice.
    Nelbach L; Shu X; Konrad RJ; Ryan RO; Forte TM
    J Lipid Res; 2008 Mar; 49(3):572-80. PubMed ID: 18056685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein A-V dependent modulation of plasma triacylglycerol: a puzzlement.
    Sharma V; Ryan RO; Forte TM
    Biochim Biophys Acta; 2012 May; 1821(5):795-9. PubMed ID: 22209939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism.
    Lookene A; Beckstead JA; Nilsson S; Olivecrona G; Ryan RO
    J Biol Chem; 2005 Jul; 280(27):25383-7. PubMed ID: 15878877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion.
    Blade AM; Fabritius MA; Hou L; Weinberg RB; Shelness GS
    J Lipid Res; 2011 Feb; 52(2):237-44. PubMed ID: 21115968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoprotein A-V: an important regulator of triglyceride metabolism.
    Kluger M; Heeren J; Merkel M
    J Inherit Metab Dis; 2008 Apr; 31(2):281-8. PubMed ID: 18415697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
    Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S
    Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol.
    Sharma V; Forte TM; Ryan RO
    Curr Opin Lipidol; 2013 Apr; 24(2):153-9. PubMed ID: 23241513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase 7 (PCSK7) reduces apoA-V levels.
    Ashraf Y; Duval S; Sachan V; Essalmani R; Susan-Resiga D; Roubtsova A; Hamelin J; Gerhardy S; Kirchhofer D; Tagliabracci VS; Prat A; Kiss RS; Seidah NG
    FEBS J; 2020 Aug; 287(16):3565-3578. PubMed ID: 31945259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects and mechanisms of apolipoprotein A-V on the regulation of lipid accumulation in cardiomyocytes.
    Luo J; Xu L; Li J; Zhao S
    Lipids Health Dis; 2018 Mar; 17(1):46. PubMed ID: 29530023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism.
    Forte TM; Ryan RO
    Curr Drug Targets; 2015; 16(12):1274-80. PubMed ID: 26028042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.
    Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein A-V; a potent triglyceride reducer.
    Nilsson SK; Heeren J; Olivecrona G; Merkel M
    Atherosclerosis; 2011 Nov; 219(1):15-21. PubMed ID: 21831376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the structure-function properties of wild-type human apoA-V and a C-terminal truncation associated with elevated plasma triglycerides.
    Stankov S; Vitali C; Park J; Nguyen D; Mayne L; Englander SW; ; Levin MG; Vujkovic M; Hand NJ; Phillips MC; Rader DJ
    medRxiv; 2023 Feb; ():. PubMed ID: 36865344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content.
    Camporez JPG; Kanda S; Petersen MC; Jornayvaz FR; Samuel VT; Bhanot S; Petersen KF; Jurczak MJ; Shulman GI
    J Lipid Res; 2015 Mar; 56(3):526-536. PubMed ID: 25548259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of apolipoprotein A-V on hepatocyte lipid droplet formation.
    Gao X; Forte TM; Ryan RO
    Biochem Biophys Res Commun; 2012 Oct; 427(2):361-5. PubMed ID: 23000161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.
    VerHague MA; Cheng D; Weinberg RB; Shelness GS
    Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2501-8. PubMed ID: 24030551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of apolipoprotein A-V concentration with apolipoprotein A5 gene -1131T>C polymorphism and fasting triglyceride levels.
    Kim JY; Kim OY; Paik JK; Lee SH; Lee JH
    J Clin Lipidol; 2013; 7(2):94-101. PubMed ID: 23415427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291).
    Sharma V; Witkowski A; Witkowska HE; Dykstra A; Simonsen JB; Nelbach L; Beckstead JA; Pullinger CR; Kane JP; Malloy MJ; Watson G; Forte TM; Ryan RO
    Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2254-60. PubMed ID: 25127531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ins (cell) and outs (plasma) of apolipoprotein A-V.
    Forte TM; Shu X; Ryan RO
    J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S150-5. PubMed ID: 19050314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.